Targeting type 2 inflammation in bullous pemphigoid (BP): dupilumab as game changer opens new avenues.
Options
BORIS DOI
Publisher DOI
PubMed ID
39657119
Date of Publication
2025-02-18
Publication Type
Article
Subject(s)
Language(s)
en
Contributor(s)
Additional Credits
Series
British Journal of Dermatology
Publisher
Oxford University Press
ISSN
1365-2133
0007-0963
Access(Rights)
embargo